Merit Medical Sees Strong Q2 Revenue Growth

Merit Medical ( (MMSI) ) has released its Q2 earnings. Here is a breakdown of the information Merit Medical presented to its investors.

Merit Medical Systems, Inc. is a global healthcare technology company specializing in the development, manufacturing, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures across various medical fields such as cardiology and radiology.

In its latest earnings report, Merit Medical announced a significant revenue increase of 13.2% for the second quarter of 2025, reaching $382.5 million. The company also reported an acquisition and a leadership change, with Martha Aronson set to become the new President and CEO later this year.

Key financial highlights include a non-GAAP operating margin increase to 21.2% from 20.1% the previous year, and a 9.8% rise in non-GAAP EPS to $1.01. The company also generated $89.1 million in free cash flow in the first half of 2025, marking an 8.1% year-over-year growth. Merit Medical’s acquisition of Biolife Delaware, a manufacturer of hemostatic devices, is expected to further strengthen its product portfolio.

Despite a slight decline in GAAP EPS by 11.6%, the company remains optimistic about its financial performance, raising its full-year revenue and non-GAAP EPS guidance. The management anticipates continued growth and profitability improvements, driven by strategic initiatives and favorable trade policies.

Looking ahead, Merit Medical is poised for a promising year with updated guidance reflecting confidence in stable growth and robust cash flow generation, underscoring the company’s strategic focus on expanding its market presence and enhancing operational efficiency.